Pharmaceutical companies are increasingly targeted by sophisticated adversaries aiming to compromise sensitive research, clinical trial data and intellectual property. With a 75% rise in healthcare-related intrusions and a sharp increase in vishing attacks, this report delivers a strategic response plan. It includes a 120-day roadmap to build cyber resilience across research and development, supply chains and regulatory operations, supported by AI-enhanced detection and protection.

Download the full report to discover how pharmaceutical organisations can secure innovation while protecting their most valuable assets.